Breakthrough DVT While Receiving Therapeutic Apixaban (Eliquis)
A confirmed new DVT occurring during therapeutic anticoagulation should be managed as anticoagulant “treatment failure” until proven otherwise. [1] Management should include verification of true recurrence and reassessment of anticoagulant exposure, then escalation of anticoagulation with a switch to therapeutic LMWH. [1], [2]
Confirmation of True Recurrent DVT
Recurrent VTE should be verified with clinical assessment and objective imaging comparison with prior studies. [1] Anticoagulant levels should be checked in patients presenting with acute VTE despite ongoing anticoagulation therapy, using an assay calibrated for apixaban when feasible. [1] Medication nonadherence is a common driver of apparent anticoagulant failure and should be assessed before medication changes. [1] New drug interactions that reduce anticoagulant efficacy should be reviewed. [1]
Immediate Anticoagulation Strategy
When a recurrent acute VTE event is suspected or confirmed while on a DOAC, initiation of weight-based therapeutic LMWH is recommended as the simplest initial strategy. [1] Patients receiving a DOAC who develop a VTE event should be switched to a different anticoagulant class. [1]
Medication Selection Algorithm
The following escalation approach is recommended for “breakthrough” VTE on anticoagulation: [1]
- Switch from a DOAC to therapeutic LMWH. [1]
- For patients already receiving LMWH at breakthrough recurrence, increase LMWH dose by ~25% to 33%. [1], [2]
- If bleeding risk prevents further anticoagulation escalation and no reversible risk factor is identified, a temporary IVC filter should be considered as a last option. [1]
Cancer and Other Underlying Causes to Reassess
Workup should include evaluation for provoking and underlying hypercoagulable conditions. [1] Recurrent VTE events are associated with acquired hypercoagulable states including antiphospholipid antibody syndrome and cancer, which should be assessed as indicated by the clinical context. [1] Outpatient hematology consultation should be arranged to discuss thrombophilia evaluation and anticoagulation options for recurrence prevention. [1]
Diagnostic and Laboratory Nuances
Anticoagulant exposure assessment should include an apixaban-calibrated anti-Xa level when available. [1] D-dimer testing and imaging comparison may support assessment of recurrence in patients presenting with suspected recurrent VTE during anticoagulation. [1]
Treatment Initiation Thresholds and Timing
A confirmed new DVT during therapeutic DOAC treatment should trigger immediate anticoagulant escalation rather than continued use of the same DOAC. [1] Therapeutic LMWH should be initiated at presentation once recurrent VTE is suspected/confirmed, using a weight-based regimen. [1]
Common Pitfalls to Avoid
Continuing the same DOAC after a confirmed “breakthrough” event without reassessing anticoagulant exposure and changing therapy is associated with continued recurrence risk. [1] Failing to verify that the event represents true recurrence (for example, not comparing new imaging to prior studies) can lead to inappropriate escalation. [1] Assuming recurrence represents pharmacologic resistance without assessing adherence and drug interactions can misclassify “treatment failure.” [1]
Targets and Goals of Therapy
The immediate goal is prevention of further thrombus propagation and recurrence by ensuring therapeutic anticoagulant intensity with LMWH after breakthrough recurrence. [1] Long-term goals include selection of an anticoagulant strategy appropriate to recurrence risk and underlying cause with hematology involvement after recurrence. [1]